On August 8, 2024, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), China's leading innovation-driven pharmaceutical company, and Guangzhou Lupeng Pharmaceutical Co., Ltd. (Lupeng Pharma), an innovative pharmaceutical company focusing on malignant tumors and autoimmune diseases，jointly announced that the two parties have entered into a licensing agreement on a small molecule Bruton's tyrosine kinase inhibitor (BTKi) LP-168 (“LP-168”) independently developed by Lupeng Pharma .
Pursuant to the licensing agreement, Hansoh Pharma has obtained an exclusive license from Lupeng Pharma to develop and commercialize LP-168 in all non-tumor indications within China (including Hong Kong, Macau and Taiwan). Hansoh Pharma will be responsible for the research and development (“R&D”) , regulatory approval, manufacturing and commercialization of LP-168 in all non-tumor indications in China, and will pay an upfront payment and potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB729 million in total, plus tiered royalties up to double-digit on future product sales.
LP-168 is a small molecule Bruton's tyrosine kinase inhibitor (BTKi). As of the date of this announcement, Lupeng Pharma is conducting various clinical studies on LP-168, with the highest stage of development in China being a Phase II pivotal clinical trial of tumor.
"Hansoh Pharma is actively seeking high-value and potential blockbuster products in the non-tumor field,” said Ms Eliza Sun, Executive Director of the Board at Hansoh,“Through this collaboration with Lupeng Pharma, we will further expand our pipeline portfolio for the treatment of autoimmune disorders and provide more medication options for patients with chronic autoimmune diseases."
Dr. Fenlai Tan, the Chairman, CEO and CMO of Lupeng Pharmaceuticals, said: "LP-168, as the next generation BTKi, has demonstrated outstanding safety profile and unique mechanism advantages in previous clinical studies. We believe that the comprehensive experience and resource from Hansoh Pharmaceuticals will accelerate the clinical development and commercialization of LP-168 in autoimmune diseases. Moreover, this will bring important breakthrough to the landscape of available treatments of immune disorders in China and even globally."
About Lupeng Pharmaceutical
Lupeng Pharmaceutical was co-founded by Dr. Tan Fenlai and Dr. Chen Yi in Guangzhou in June 2018. The company focus on key targets such as BTK, Bcl-2, and Bcl-xL in hematological tumors, and it dedicated to developing innovative drugs for cancer and autoimmune diseases.
With strong R&D capacity, Lupeng is at the cutting-edge of medical innovation and has more than 10 programs, among which the core programs Rocbrutinib (LP-168) and Lacutoclax (LP-108) have been approved by the National Medical Products Administration for pivital registration trials. Rocbrutinib, Lacutoclax, and LP-118 are highly competitive and are expected to become the BIC (Best-in-Class) new drugs.
Lupeng has continuously received investment and support from many international and domestic widely known biopharmaceutical venture capital funds. Lupeng is committed to becoming an innovative and globally competitive biopharmaceutical company with a whole-industry-chain layout that encompasses R&D, manufacturing and commercialization. in the Greater Bay Area.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
